Premium
The metabolic syndrome and its components in pediatric survivors of allogeneic hematopoietic stem cell transplantation
Author(s) -
Bielorai Bella,
Weintraub Yael,
Hutt Daphna,
Hemi Rina,
Kanety Hannah,
ModanMoses Dalit,
Goldstein Gal,
Hadar Dana,
LernerGeva Liat,
Toren Amos,
PinhasHamiel Orit
Publication year - 2017
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.12903
Subject(s) - medicine , metabolic syndrome , adiponectin , hematopoietic stem cell transplantation , hypertriglyceridemia , overweight , body mass index , uric acid , transplantation , obesity , insulin resistance , cholesterol , triglyceride
Metabolic syndrome (MetS) is a known complication after hematopoietic stem cell transplantations ( HSCT ) that contributes to long‐term morbidity. We assessed the prevalence of components of the MetS in pediatric survivors of allogeneic HSCT and identified associated risk factors. Thirty‐eight patients, median age at HSCT , 8.5 years, were evaluated at a median of 3.9 years post‐ HSCT . Overweight or obesity was seen in 23.7% of the patients, 15.8% had hypertension, 15.8% had hypertriglyceridemia, and 13% had low high‐density lipoprotein cholesterol levels according to age and gender. Four (10.5%) met the criteria of MetS; all were transplanted for malignant disease. Twelve patients (31.6%) had at least one component of the MetS. The 5‐year probability of developing components of the MetS revealed that patients with BMI ‐ Z score ≥0 at HSCT were significantly at higher risk than those with lower BMI ‐ Z . Patients who developed components of the MetS had higher levels of insulin, homeostasis model assessment, uric acid, leptin, and lower adiponectin levels. Multivariable regression analysis revealed that BMI ‐ Z ‐score >1.036 at time of evaluation was associated with 4.3‐fold increased risk ( P =.050) and adiponectin levels ≤6 μg/mL were associated with 6.7‐fold increased risk of develop components of the MetS ( P =.007). Overweight and obesity and adiponectin levels may be useful as markers in HSCT survivors.